Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: HYTRIN

« Back to Dashboard

Hytrin is a drug marketed by Abbott and is included in two NDAs.

The generic ingredient in HYTRIN is terazosin hydrochloride. There are twenty-four drug master file entries for this compound. Additional details are available on the terazosin hydrochloride profile page.

Summary for Tradename: HYTRIN

Patents:0
Applicants:1
NDAs:2

Clinical Trials for: HYTRIN

Pilot Study of Terazosin in Treatment of Antidepressant Induced Excessive Sweating
Status: Completed Condition: Antidepressant Induced Excessive Sweating

FLOMAX® Versus HYTRIN® in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia
Status: Completed Condition: Prostatic Hyperplasia

Excessive Sweating Caused by Antidepressants: Measurement and Treatment With Terazosin
Status: Completed Condition: Hyperhidrosis

Effect of Amlodipine Monotherapy or Combined With Terazosin on Lower Urinary Tract Symptoms and Hypertension
Status: Completed Condition: Lower Urinary Tract Symptoms; Hypertension

A Pharmacodynamic Study of Dapoxetine Concomitantly Administered in Participants Taking Terazosin
Status: Completed Condition: Ejaculation

The Effect of Terazosin and Tolterodine on Ureteral Stent Related Symptoms
Status: Completed Condition: Disorder of Urinary Stent

Randomized Trial Comparing Terazosin 5 mg Daily and Doxazosin GITS 4 mg Daily for Trial Without Catheter in Acute Urinary Retention With Long Term Follow up
Status: Terminated Condition: Prostatic Hyperplasia; Urinary Retention

Diesel Exhaust and Vascular Function
Status: Recruiting Condition: Cardiovascular Effects

Alpha-blocker Plus Diuretic Combination Therapy as Second-line Treatment for Nocturia in Men
Status: Completed Condition: Nocturia

The Clinical Efficacy of Non-steroidal Anti-inflammation Drugs in Patients With Benign Prostatic Hyperplasia
Status: Withdrawn Condition: Benign Prostatic Hyperplasia

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbott
HYTRIN
terazosin hydrochloride
CAPSULE;ORAL020347Dec 14, 1994DISCNNo<disabled><disabled>
Abbott
HYTRIN
terazosin hydrochloride
TABLET;ORAL019057Aug 7, 1987DISCNNo<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc